Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Recombinant fragment contain a sequence corresponding to a region within amino acids 192 and 469 of SLA/LP|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7, with 1% BSA, 20% glycerol|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100-1:1000|
|Western Blot (WB)||1:1000-1:10,000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-32121 targets SLA/LP in WB applications and shows reactivity with Human samples.
The PA5-32121 immunogen is a recombinant fragment corresponding to a region within amino acids 192 and 469 of SLA/LP.
The 21st amino acid, selenocysteine (sec), is distinct from other amino acids because it lacks its own tRNA synthetase and is the only amino acid synthesized on its cognate tRNA. Synthesis of sec begins with acylation of tRNA(sec) (TRSP; MIM 165060) by seryl-tRNA synthetase (SARS; MIM 607529) to give ser-tRNA(sec), which is subsequently phosphorylated by O-phosphoseryl-tRNA kinase (PSTK; MIM 611310) to give O-phosphoseryl-tRNA(sec). SEPSECS catalyzes the final step of sec synthesis by converting O-phosphoseryl-tRNA(sec) to selenocysteinyl-tRNA(sec) using selenophosphate as the selenium donor (Palioura et al., 2009 [PubMed 19608919]).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
liver-pancreas antigen; LP; PCH2D; SLA; SLA-p35; SLA/LP; SLA/LP autoantigen; soluble liver antigen; soluble liver antigen/liver pancreas antigen; tRNA(Ser/Sec)-associated antigenic protein; UGA suppressor tRNA-associated protein
LP; PCH2D; SEPSECS; SLA; SLA/LP; TRNP48